Akero Therapeutics (AKRO) Financials

$54.65

$0.00 (0.00%)

As on 09-Dec-2025 09:30EDT

Market cap

$4,499 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

4.7

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Operating Revenue	0.00	--	--	--	--	--
Cost of Revenue	0.00	0.02	0.03	0.26	100.89	80.15
Gross Profit	0.00	-0.02	-0.03	-0.26	-100.89	-80.15
Operating Expenses	330.02	285.42	172.87	115.16	100.89	80.15
Operating Profit (EBIT)	-330.02	-285.42	-172.87	-115.16	-100.89	-80.15
Other Income	--	--	--	3.93	0.09	0.95
Profit before Tax	-292.82	-252.06	-151.76	-112.03	-100.78	-79.21
Provision for Tax	--	--	--	-3.12	-0.04	-0.02
Profit after Tax (Net Income)	-292.82	-252.06	-151.76	-112.03	-100.74	-79.19
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	-112.03	-100.78	-79.21

Liabilities ($ Mln)	TTM	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Shareholder's Funds	957.64	750.11	535.31	326.56	169.11	258.71
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	0.29	36.02	25.84	10.93	1.31	1.52
Current Liabilities	47.65	39.75	19.13	19.08	25.13	13.11
Total Liabilities	1,053.23	825.89	580.27	356.57	195.55	273.34

Assets ($ Mln)	TTM	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Non-Current Assets	251.04	55.51	20.31	1.40	1.97	1.99
Current Assets	754.54	770.38	559.96	355.17	193.58	271.35
Total Assets	1,053.23	825.89	580.27	356.57	195.55	273.34
Total Debt*	1.16	36.46	26.31	10.95	1.52	1.81
Net Current Assets	706.88	730.63	540.83	336.09	168.45	258.23

Cashflow ($ Mln)	TTM	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Cash From Operating Activities	--	-230.11	-145.37	-92.52	-79.68	-70.80
Cash Flow from Investing Activities	--	-109.71	-223.62	-63.83	42.28	-9.76
Cash from Financing Activities	--	445.85	353.32	255.63	0.60	203.11
Net Cash Inflow / Outflow	--	--	--	99.29	-36.80	122.54

Financials Ratios	TTM	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Adjusted EPS ($)	-3.75	-3.57	-2.72	-2.40	-2.89	-2.28
Cash EPS ($)	--	-3.57	-2.72	-2.39	-2.89	-2.28
Adjusted Book Value ($)	--	10.63	9.61	6.98	4.85	7.46
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-3.26	-2.61	-1.98	-2.28	-2.04
Free Cash Flow per Share ($)	--	-3.27	-2.61	-1.98	-2.28	-2.05

Profitability Ratios	TTM	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
ROCE (%)	--	-37.39	-33.76	-44.10	-46.73	-40.68
ROE (%)	-28.69	-39.22	-35.22	-45.20	-47.09	-40.88
ROA (%)	-30.60	-35.85	-32.40	-40.58	-42.97	-38.49
EBIT Margin (%)	-7,205,162.50	--	--	--	--	--
Net Margin (%)	-7,320,500.00	--	--	-2,853.62	-118,512.94	-8,335.79
Cash Profit Margin (%)	-488.03	--	--	--	--	--

Growth Ratios	TTM	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Revenue Growth (%)	-98.59	--	--	--	--	--
EBIT Growth (%)	-23.77	-66.41	-33.57	-10.32	-25.87	-75.58
Net Profit Growth (%)	-23.44	-66.09	-35.46	-11.21	-27.21	-80.99
EPS Growth (%)	-0.06	-0.31	-0.14	0.17	-0.26	-0.48
Book Value Growth (%)	9.83	--	--	--	--	--

Valuation Ratios	TTM	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Price / Earnings	--	-7.79	-8.57	-22.87	-7.32	-11.30
Price / Book Value	4.70	2.62	2.43	7.85	4.36	3.46
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-6.77	-5.08	-5.23	-19.97	-5.46	-7.84
Close Price ($)	47.48	27.82	23.35	54.80	21.15	25.80
High Price ($)	58.40	37.00	58.38	54.83	34.87	41.16
Low Price ($)	21.34	15.32	11.25	7.52	17.66	10.78
Market Cap ($ Cr)	4,499.03	--	--	--	--	--

Solvency Ratios	TTM	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Debt to Equity	--	0.05	0.05	0.03	0.01	0.01
Short term debt to equity ratio	0.00	0.00	0.00	0.00	0.00	0.00
Current Ratio	15.83	19.38	29.27	18.61	7.70	20.70
Quick Ratio	15.83	--	--	--	--	--
Interest Coverage	-62.41	-53.00	-47.97	-150.60	-2,460.63	--

Operating Efficiency Ratios	TTM	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Debtors to sales (%)	--	--	--	--	--	--
Asset Turnover	0.00	--	--	--	--	--
Receivable days	--	--	--	--	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	162,992.81	94,498.99	10,307.07	18.34	9.97
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.